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pen accessAbstract Background: Although being used off-label, the utility of dexmedetomidine in pediatric
settings is increasing. Alpha-2 agonists have peripheral analgesic effects. This prospective, random-
ized, double-blind, Placebo-controlled study was designed to evaluate the safety and efﬁcacy of
dexmedetomidine single intraoperative preincisional dose in pediatric patients undergoing tonsillec-
tomy and adenoidectomy.
Patients and methods: Eighty-four children (5–12 years) were randomized into three groups:
DEX.IV (n= 28) received dexmedetomidine 1 lg/kg iv. infusion in 10 min, DEX.PT (n= 28)
received dexmedetomidine 1 lg/kg peritonsillar inﬁltration, and the Placebo controls (n= 28).
Assessment parameters included pain, sedation, hemodynamics, and adverse effects.
Results: Intraoperative dexmedetomidine administration resulted in a signiﬁcant reduction in pain
scores postoperatively in the DEX.IV and DEX.PT groups, with no signiﬁcant difference between
them. The time to ﬁrst postoperative analgesic request was signiﬁcantly prolonged in DEX.IV
(583.45 ± 157.94 min, P< 0.000) and DEX.PT (537.61 ± 106.17 min, P< 0.000) groups com-
pared with the Placebo group (119.75 ± 43.44 min). Similarly, a signiﬁcantly lower paracetamol2010381x2011; fax: +20 88
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-Haleem).
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220 H.S. Abdel-ghaffar, A.K. Abdel-Haleemconsumption during the ﬁrst postoperative day was recorded in the DEX.IV (459.37 ± 114.82 mg,
P< 0.000) and DEX.PT (475.38 ± 143.11 mg, P< 0.000) groups, than in the Placebo group
(705.00 ± 249.27 mg), with no signiﬁcant difference between DEX.IV and DEX.PT groups. Patients
in the DEX.IV group exhibited signiﬁcantly prolonged extubation times ((13.83 ± 3.38 min,
P< 0.000) and signiﬁcantly highermeanRamsay sedation scores at 15, 30, 60, 120, and 180 min post-
operative (P< 0.000), compared with DEX.PT and Placebo groups. The mean intraoperative heart
rates were signiﬁcantly slower in DEX.IV group during and after the intravenous infusion of dex-
medetomidine and at 15th min intraoperative (p< 0.05), compared with DEX.PT and Placebo
groups, with no signiﬁcant differences inmean heart rates among the groups in other time pointsmea-
sured. Patients in DEX.PT group had a signiﬁcantly higher total oral intake in ﬁrst day postoperative
(P< 0.000) and a signiﬁcantly higher family satisfaction (p< 0.000), compared with DEX.IV and
Placebo groups.
Conclusion: Peritonsillar inﬁltration or iv. dexmedetomidine similarly enhanced the postoperative
analgesia after tonsillectomy in pediatric patients. However, locally applied dexmedetomidine was
associated with no systemic effects, higher total oral intake in ﬁrst day postoperative, and higher fam-
ily satisfaction.
ª 2011 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Dexmedetomidine (DEX) (Precedex; Hospira, Inc.Lake For-
est, IL) is a highly selective a2-adrenoceptor agonist recently
introduced to anesthesia practice producing dose-dependent
sedation, anxiolysis, and analgesia (involving spinal and
supraspinal sites), without respiratory depression [1,2]. Com-
pared with Clonidine, DEX is a more speciﬁc and selective
a2-adrenergic agonist with a shorter elimination half-life [3].
Its only approved indication by US FDA (1999) is the provi-
sion of short term sedation (<24 h) in adult patients in ICU
settings who are initially intubated and mechanically venti-
lated [4].
DEX is being used off-label as an adjunctive agent in pedi-
atric patients for sedation and analgesia; in critical care unit,
during non-invasive (e.g., Magnetic resonance imaging) and
invasive procedures (e.g., cardiac catheterization and endos-
copy) [5]. It may also decrease opioid usage and anesthesia
requirements as seen from adult data [6], prevent emergence
delirium [7] and postanesthesia shivering [8].
Pediatric experiences in the literature are in the form of
small studies and case reports [1], with limited data regard-
ing the use of dexmedetomidine as a premedication for anx-
iolysis and postoperative pain. The appropriate dose and
route of administration of such application are still under
investigation.
Tonsillectomy and adenoidectomy are among the most
common surgical procedures in pediatric population, and post-
tonsillectomy pain is still a debate [9,10], affecting the analgesic
consumption, hospital stay, oral intake, and return to regular
activity [10,11].
Alpha-2 adrenergic agonists have peripheral analgesic ef-
fects [12]. Therefore, this study was designed to compare the
effects of dexmedetomidine 1 lg/kg single intraoperative dose
given by two different routes of administration, intravenous
and peritonsillar inﬁltration, on postoperative recovery includ-
ing pain, sedation, and hemodynamics in pediatric patients
undergoing tonsillectomy and adenoidectomy, and the record-
ing of any adverse effects that might develop during the 24-h
study period.2. Patients and methods
This prospective, randomized, double-blind, Placebo-con-
trolled study was approved from the local research Ethics
Committee in the faculty of medicine, Assiut University,
Egypt. The study included 84 patients (aged 5–12 years),
ASA I-II scheduled for elective tonsillectomy with or without
adenoidectomy (using the surgical retraction and bipolar
diathermy if indicated). An informed written consent was ob-
tained from all the patient’s legal guardians.
The indications for tonsillectomy were recurrent or chronic
tonsillitis. Excluded from the study are patients with the
following conditions: obstructive sleep apnea syndrome
(whether conﬁrmed by a polysomnography test or not), previ-
ous peritonsillar abscess formation, cardiovascular, liver or
renal disease, unsatisfactory preoperative peripheral arterial
oxygen saturation, neurological or psychiatric disease, coagu-
lation disturbances, relevant drug allergies, difﬁculties in pain
perception and assessment, and lastly, children with a BMI
>95th percentile for age .
Based on a computer-generated randomization method,
patients were enrolled into three groups: I-DEX.IV: patients
(n= 28) received dexmedetomidine 1 lg/kg diluted in 50 ml
saline 0.9% and given by iv. infusion in 10 min after induc-
tion of anesthesia and peritonsillar saline inﬁltration (2 ml
per tonsil). II-DEX.PT: patients (n= 28) received dexmede-
tomidine 1 lg/kg diluted in 4 ml saline 0.9% and given by
peritonsillar inﬁltration (2 ml per tonsil), after intubation 3–
5 min before start of surgery. Using a 25-gauge spinal needle
connected to a syringe, the tonsillar bed and peritonsillar tis-
sues on both sides were inﬁltrated in a fan-wise injections
from the superior and inferior poles of the fossa. Patients also
received 50 ml saline 0.9% infusion after anesthetic induction
in 10 min. III-Placebo: patients (n= 28) received 50 ml saline
0.9% iv. infusion and 4 ml saline 0.9% peritonsillar inﬁltra-
tion (2 ml per tonsil), at the same time points mentioned
above. The dose of dexmedetomidine selected (1 lg/kg) was
based on previous studies that conﬁrmed the analgesic efﬁ-
cacy of dexmedetomidine 1 lg/kg rather than 0.5 lg/kg and
0.75 lg/kg [13].
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were instructed in how to use the pain assessment tool of ver-
bal numeric rating pain scale [14] ranging from 0 to 10 (with
zero = no pain and 10 = the worst pain imaginable).
The anesthetic regimen was standardized; it included induc-
tion with propofol 2–3 mg/kg and atracurium besylate 0.5 mg/
kg to facilitate endotracheal intubation and maintenance with
isoﬂurane and oxygen/air mixture. Intraoperative monitoring
included ECG, pulse oximeter, non-invasive blood pressure,
and end-tidal CO2. An intravenous antibiotic and dexamet-
hazone (0.2 mg/kg, max. dose 8 mg) were administered. No
opioids, NSAIDS, paracetamol, or additional propofol were
used during the procedure. At the end of the operation, neuro-
muscular blockade was antagonized with neostigmine 0.05 mg/
kg and atropine 0.02 mg/kg, and patients were turned aside in
the posttonsillectomy recovery position. Patients extubated
awake after conﬁrming the return of airway protective reﬂexes
and transported to (PACU), with supplemental oxygen that
discontinued if the child could sustain a SaO2% >95% for
5 min on room air. After attaining an Aldrete score [15] P9,
patients were moved from PACU to the ward. Patient care
or data collection personnel and the surgeon were blinded to
the patient assignment.
Operative room data were included; heart rate and mean
arterial blood pressure were continuously monitored and re-
corded preoperatively, before, during, and after the adminis-
tration of the study solutions, and at 15th, 20th, 25th, and
30th min intraoperative; anesthesia time (from induction of
anesthesia till extubation); operative time (from start of sur-
gery till end of bleeding control); and extubation time (from
discontinuation of anesthesia till extubation).
PACU and ward data were included; heart rate and mean
arterial blood pressure were measured and recorded on arrival
in the PACU (0 min) and at 15th, 30th, 45th, and 60th min
postoperative; Ramsay sedation scale [16] scores measured at
0 (on arrival in the PACU), 15, 30, 60, 120, 180 and 240 min
postoperative; time to ﬁrst and subsequent request of supple-
mental analgesics and total dose of rescue analgesics consumed
postoperative; total oral intake in ﬁrst 24 h postoperative
including ﬂuids and semisolids. The Children’s Hospital of
Eastern Ontario (CHEOPS) [17] pain scale (children <7 years)
or the verbal numeric rating scale [14] (children 7–12 years)
were measured at 0 (on arrival at PACU), 30, 60, and
90 min postoperative. They were also recorded at 2, 6, and
12 h postoperative, and the mean value of the three values
was calculated and recorded as the mean CHEOPS or VNRSTable 1 Demographic and recovery characteristics.
Placebo (n= 28) DEX.IV
Age (year) 8.92 ± 2.53 8.26 ±
Weight (kg) 30.60 ± 6.61 28.85 ±
Sex (M/F) 17/11 15/13
Tonsill./adenotonsill. 21/7 20/8
Anesth. time (min) 46.67 ± 6.11 53.67 ±
Operat. time (min) 34.25 ± 5.86 34.92 ±
Extubat. time (min) 6.57 ± 1.77 13.83 ±
Total oral ﬂuid intake/24 h (/ml) 592.85 ± 132.10 648.57
Total oral semisolid intake/24 h (ml) 332.14 ± 108.84 473.21
Data expressed as mean ± SD, and number.
P1: Signiﬁcance between Placebo and DEX.IV. P2: Signiﬁcance between Pscores in the ﬁrst day postoperative. Paracetamol (Perfalgan,
Bristol Meyers Squibb, New York) 15 mg/kg iv. was given if
requested and if VNRS scores were P3 or CHEOPES scores
were >8.
Perioperative side effects were treated and recorded (e.g.,
hypertension, hypotension, bradycardia, tachycardia, arrhyth-
mia, hypoxia, nausea, vomiting, excess secretions, bleeding
and respiratory depression). The children’s families graded
their satisfaction regarding analgesia (very satisﬁed, mildly sat-
isﬁed, or not satisﬁed) at the end of the 24-h study period.3. Statistical analysis
The primary outcome measure was the total dose of analgesics
consumed in the ﬁrst day postoperative. Secondary outcome
measures were time to ﬁrst request of rescue analgesics, num-
ber of patients who needed more than 1 analgesic dose, time
to extubation, Ramsay sedation score, heart rate, mean arterial
pressure, total oral intake in ﬁrst 24 h postoperative, and the
incidence of postoperative side effects.
Sample size: in our institution, we annually anesthetize 480–
768 (10–16/week) tonsillectomy and adenoidectomy case suf-
fering from chronic or recurrent tonsillitis. Previous studies
on adults reported 33% decrease in morphine use postopera-
tively when using dexmedetomidine iv. 0.4 lg/kg [18] and
66% decrease when using dexmedetomidine 1 l/kg iv. [19],
with no available published data about dexmedetomidine per-
itonsillar administration. Our power analysis was based on
estimating a 20% reduction in analgesic requirements in a
sample population of 600. A calculated sample size of 28
would have an 80% power of detecting a difference at 0.05
level of signiﬁcance, using a conﬁdence interval of 95%.
Analysis was performed using SPSS version 17 (Chicago-
USA). Data were presented as mean ± SD, numbers, frequen-
cies, and percentages. ANOVA followed by post hoc test were
used for comparison of parametric data. Kruskal–Wallis test
was used to compare non-parametric data while Mann–Whit-
ney used to compare between two groups. Chi-square test was
used for comparison between percentages and frequencies.
P< 0.05 was considered signiﬁcant.4. Results
One hundred ﬁfty-six patients who qualiﬁed for the study were
approached: 84 consented and 72 refused. The consented 84(n= 28) DEX.PT (n= 28) P1 P2 P3
2.35 8.60 ± 2.31 0.317 0.622 0.589
8.35 30.28 ± 8.70 0.286 0.304 0.292
13/15 0.431 0.541 0.429
21/7 0.502 0.374 –
7.29 46.75 ± 6.88 0.000 0.967 0.001
5.36 33.50 ± 6.77 0.653 0.659 0.385
3.38 6.19 ± 1.80 0.000 0.436 0.000
± 88.89 687.14 ± 123.10 0.07 0.008 0.185
± 146.51 607.85 ± 143.04 0.000 0.000 0.001
lacebo and DEX.PT. P3: Signiﬁcance between DEX.IV and DEX.PT.
Table 2 Pain proﬁle.
Placebo
(n= 28)
DEX.IV
(n= 28)
DEX.PT
(n= 28)
P1 P2 P3
Request time
(min)
119.75 ± 43.44 583.45 ± 157.94 537.6 ± 106.17 0.000 0.000 0.231
Request no.
No request – 4 2 0.03 0.295 0.204
One dose 17 22 24 0.01 0.04 0.524
Two doses 11 2 2 – – –
>Two doses – – – – – –
Paracetamol iv.
total dose/mg
705.00 ± 249.27 459.38 ± 114.82 475.38 ± 143.11 0.000 0.000 0.666
CHEOPS score
0 min 7.62 ± 1.14 6.00 ± 0.80 6.24 ± 0.91 0.01 0.05 0.591
30th min 8.21 ± 1.91 6.15 ± 0.95 6.46 ± 1.16 0.03 0.05 0.667
60th min 8.92 ± 2.11 6.17 ± 0.92 6.81 ± 2.15 0.01 0.05 0.675
90th min 9.65 ± 2.64 6.16 ± 0.89 6.86 ± 1.94 0.001 0.01 0.654
Mean CHEOPS
for ﬁrst day
postoperat.
9.34 ± 0.91
(n= 11)
6.98 ± 0.86
(n= 13)
7.12 ± 0.81
(n= 12)
0.001 0.003 0.673
VNRS score
0 min 3.21 ± 1.62 0.91 ± 0.86 0.92 ± 0.95 0.000 0.000 0.193
30th min 3.64 ± 1.91 1.2 ± 0.94 1.4 ± 0.93 0.000 0.000 0.186
60th min 4.15 ± 2.16 1.6 ± 0.83 1.9 ± 0.86 0.000 0.000 0.180
90th min 4.36 ± 1.85 1.8 ± 1.12 2.4 ± 0.95 0.001 0.01 0.185
Mean VNRS for
ﬁrst day
postoperat.
3.88 ± 0.34
(n= 17)
2.45 ± 0.31
(n= 15)
2.59 ± 0.27
(n= 16)
0.001 0.001 0.184
Data expressed as mean ± SD and number.
CHEOPS: Children’s Hospital of Eastern Ontario pain scale (children <7 years).
VNRS: Verbal numeric rating pain scale (children 7–12 years).
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patient dropouts. All procedures were performed by 1 of 4 oto-
laryngologic surgeons with an even distribution of cases among
the 4. There were no differences among the groups of patients
with regard to age, weight, gender, and duration of surgery (Ta-
ble 1). The time to extubation was signiﬁcantly prolonged in the
DEX.IV group (13.83 ± 3.38 min, P< 0.000), compared with
the DEX.PT (6.19 ± 1.80 min) and Placebo (6.57 ± 1.77 min)
groups, leading to a signiﬁcantly prolonged anesthesia times in
DEX.IV. (53.67 ± 7.29 min, P< 0.000), but not the DEX.PT
(46.75 ± 6.88 min) or the Placebo (46.67 ± 6.11 min) groups,
respectively (Table 1).The highest mean values of 24-h total
oral intake for ﬂuids and semisolids were achieved in the
DEX.PT group (687.14 ± 123.10 ml and 607.85 ± 143.04 ml,
P< 0.000), compared to the DEX.IV (648.57 ± 88.89 ml
and 473.21 ± 146.51 ml) and Placebo (592.85 ± 132.10 ml
and 332.14 ± 108.84 ml) groups, respectively (Table 1).
The mean time to ﬁrst request of rescue analgesia was
signiﬁcantly prolonged in DEX.IV (583.45 ± 157.94 min,
P< 0.000) and DEX.PT (537.61 ± 106.17 min, P< 0.000)
groups compared to the Placebo group (119.75 ± 43.44 min).
The number of patients required >1 rescue analgesic dose was
higher in the Placebo group (n= 11/30.8%), compared to
DEX.IV (n= 2/5.6%) and DEX.PT (n= 2/5.6%) groups.
The mean total dose of iv. paracetamol rescue analgesia con-
sumed in ﬁrst 24 h postoperative was signiﬁcantly lower in
DEX.IV (459.37 ± 114.82 mg, P< 0.000), and DEX.PT
(475.38 ± 143.11 mg, P< 0.000) groups, but not the Placebogroup (705.00 ± 249.27 mg) (Table 2). Pain scores recorded at
0, 30, 60, and 90 min postoperative were signiﬁcantly lower in
DEX.IV and DEX.PT groups compared to Placebo (Table 2).
Moreover, themeanCHEOPS andVNRSpain scores in the ﬁrst
day postoperative were signiﬁcantly reduced in DEX.IV
(6.98 ± 0.86, p< 0.001 and 2.45 ± 0.31, p< 0.000) and
DEX.PT (7.12 ± 0.81, p< 0.003 and 2.59 ± 0.27, p< 0.001)
groups, compared to the Placebo group (9.34 ± 0.91 and
3.88 ± 0.34), respectively.
The Ramsay sedation score in the ﬁrst 240 min postopera-
tive decreased over time in all three groups. However, mean
sedation scores were signiﬁcantly higher in DEX.IV group
(P< 0.000) compared to DEX.PT and Placebo groups at
15, 30, 60, 120, and 180 min postoperative (Table 3, Fig. 1).
The mean intraoperative heart rates were signiﬁcantly
slower in DEX.IV group during and after the intravenous infu-
sion of dexmedetomidine and at 15th min intraoperative
(p< 0.05), compared with DEX.PT and Placebo groups
(Table 4). Moreover, two patients in the DEX.IV group man-
ifested signiﬁcant intraoperative bradycardia (>20% of base-
line). The ﬁrst patient showed bradycardia and desaturation
(SaO2%= 91%) lasted < 60 s during the infusion of dex-
medetomidine and resolved without treatment. The second pa-
tient had two attacks of bradycardia, after the end of
dexmedetomidine iv. infusion and at the end of operation that
necessitated iv. atropine administration (20 lg/kg). Otherwise,
there were no signiﬁcant differences in mean heart rates among
the groups in other time points measured (Table 4).
Table 3 Ramsay sedation score.
0 min 15 min 30 min 60 min 120 min 180 min 240 min
Placebo (n= 28) 4.57 ± 0.63 3.82 ± 0.54 3.32 ± 0.47 2.89 ± 0.62 2.25 ± 0.44 2.03 ± 0.188 2.00 ± 0.00
DEX.IV (n= 28) 4.96 ± 0.63 4.71 ± 0.71 4.07 ± 0.46 3.60 ± 0.62 2.89 ± 0.41 2.53 ± 0.50 2.035 ± 0.188
DEX.PT (n= 28) 4.64 ± 0.67 3.71 ± 0.53 3.39 ± 0.49 2.92 ± 0.66 2.28 ± 0.46 2.07 ± 0.26 2.00 ± 0.00
P1 0.025 0.000 0.000 0.000 0.000 0.000 0.352
P2 0.686 0.462 0.585 0.837 0.768 0.561 0.741
P3 0.073 0.000 0.000 0.000 0.000 0.000 0.322
Data expressed as mean ± SD.
S0 min. S15 min. S30 min. S60 min. S120 min. S180 min. S240 min.
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Group I 4.57 3.82 3.32 2.89 2.25 2.03 2
Group II 4.96 4.71 4.07 3.6 2.89 2.53 2.035
Group III 4.64 3.71 3.39 2.92 2.28 2.07 2
Figure 1 Ramsay mean sedation scores.
Table 4 The heart rate (beat/min).
Heart rate beat/
min
Placebo DEX.IV DEX.PT P1 P2 P3
Preoperat. 91.4 ± 8.9 92.3 ± 9.2 91.8 ± 9.6 0.592 0.597 0.425
Intraoperat.
Before 108.5 ± 10.1 105.6 ± 9.9 103.8 ± 10.3 0.478 0.533 0.534
During 116.3 ± 9.7 92.6 ± 10.3\ 108.7 ± 9.6 0.03 0.284 0.374
After 113.8 ± 10.6 91.3 ± 7.9\ 106.6 ± 10.1 0.01 0.354 0.428
15th min 105.3 ± 8.9 93.6 ± 8.4\ 103.4 ± 9.8 0.02 0.278 0.278
20th min 101.8 ± 9.3 92.4 ± 8.1 100.5 ± 8.7 0.364 0.406 0.325
25th min 98.4 ± 9.7 92.6 ± 8.9 95.2 ± 8.1 0.375 0.374 0.427
30th min 97.6 ± 9.3 90.4 ± 9.1 94.1 ± 7.9 0.423 0.502 0.342
Postoperat.
0 min 89.8 ± 7.6 84.6 ± 7.3 88.9 ± 8.1 0.472 0.564 0.508
15th min 90.6 ± 6.8 83.4 ± 6.9 89.1 ± 7.7 0.243 0.427 0.425
30th min 90.4 ± 7.1 84.1 ± 7.7 90.3 ± 6.8 0.352 0.374 0.342
45th min 93.6 ± 8.2 84.5 ± 6.7 90.6 ± 7.4 0.472 0.475 0.298
60th min 95.8 ± 7.5 85.2 ± 6.4 91.1 ± 6.9 0.354 0.378 0.352
Data expressed as mean ± SD.
Before, during, and after: before, during, and after the intravenous infusion of the study solutions.
P1: Signiﬁcance between Placebo and DEX.IV. P2: Signiﬁcance between Placebo and DEX.PT. P3: Signiﬁcance between DEX.IV and DEX.PT.
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and 6 complained from excessive secretions with no intergroup
statistical differences. No patient reported prolonged supple-
mental oxygen requirements, hypo or hypertension, tachycar-dia, arrhythmia, respiratory depression, or tonsillar bed
bleeding. Finally, a signiﬁcantly higher family satisfaction (Ta-
ble 5) was recorded in DEX.PT group (p< 0.000), compared
to DEX.IV and Placebo groups.
Table 5 Family satisfaction index.
Very satisﬁed Mildly satisﬁed Not satisﬁed
Placebo – 13 (46.42%) 15 (53.57%)
DEX.IV 6 (21.42%) 14 (50%) 8 (28.57%)
DEX.PT 18 (64.28%)\ 10 (35.70%) –
P value <0.000
Data are expressed as number and percentage.
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The main ﬁnding in this study was that both intravenous and
peritonsillar dexmedetomidine in a dose of 1 lg/kg adminis-
tered intraoperatively before the start of adenotonsillectomy
surgery, enhanced postoperative pain relief, prolonged time
to ﬁrst request and reduced the need for postoperative analge-
sia. Peritonsillar dexmedetomidine produced comparable anal-
gesia, earlier recovery, less sedation, less bradycardia, higher
total oral intake in ﬁrst day postoperative, and a higher family
satisfaction compared to intravenous dexmedetomidine.
The analgesic effects of a2-adrenergic agonists could bemed-
iated through supraspinal, spinal and peripheral actions [20].
The reduction in analgesic requirements in this study was in
accordance with previous adult [19,21] and pediatric [22–24]
studies which concluded that intraoperative administration of
dexmedetomidine signiﬁcantly reduces postoperative opioid
analgesic requirements. The difference in our study is the use
of paracetamol iv. rescue analgesia, as our institution protocols
prefer non-opioid analgesia for posttonsillectomy pain.
In this study, the lack of systemic effects in the peritonsillar
dexmedetomidine group suggests the possibility of a direct lo-
cal action. But we cannot exclude a central analgesic effect
resulting from systemic absorption; because of the similar
analgesic proﬁle observed between intravenous and peritonsil-
lar groups, and the rich vascularity of the peritonsillar area.
Unfortunately, we did not measure the plasma concentration
of dexmedetomidine to correlate it with the clinical ﬁndings
that might have conﬁrmed the local effects. Further studies
are needed to deﬁne the optimum analgesic dose of peritonsil-
lar dexmedetomidine and to clarify its local adverse effects in
pediatric population. A future research question arises: can
we select between combined effects of dexmedetomidine by
changing the route of administration?
The sedative effect of dexmedetomidine is characterized by
being short term and easily arousable ‘‘Arousable sedation’’
[25]. Other clinically available sedatives failed to produce such
sedation. This feature was shown by Hall and colleagues who
used the Bispectral index system and psychometric tests such
as the Visual Analogue Scale for Sedation, Observer’s Assess-
ment of Alertness/Sedation Scale, Digit Symbol Substitution
Scale, and speciﬁc memory tests. In accordance with our re-
sults, these parameters showed reduced values by dexmede-
tomidine administration that returned to baseline 4 h after
treatment [26]. Moreover, the Bispectral index system returned
from 60 to 65 before stimulus back to normal values when
encouraged [26]. A larger European phase III trial underlined
these ﬁndings, stating that even complex tasks, such as com-
munication by pen and paper, are possible under dexmedetom-
idine primary therapy [25].
In our study, the analgesic effect of iv. dexmedetomidine
1 lg/kg was appreciated; however, its prolonged recovery timesand arousable short term sedation annoyed the children’s next
of kin and delayed oral intake. This study was investigated in
healthy subjects undergoing a relatively moderate operation
under ambulatory conditions. And so, even mild sedation for
2–3 h postoperative delays the time to discharge readiness
and time of ﬁrst oral intake. Such sedation would be preferable
in patients undergoing major operations such as cardiothoracic
surgery and in critical care settings. For dexmedetomidine,
appropriate patient selection is crucial [5], and also the type
of surgical procedure is important. Procedure-speciﬁc acute
pain management guidelines may be helpful, taking into con-
sideration that the risk–beneﬁt ratio of different analgesics
may vary according to the surgical procedure [27–29].
In the current study, slower intraoperative mean heart rates
were observed during and after the intravenous infusion of
dexmedetomidine 1 lg/kg (including two cases with signiﬁcant
bradycardia). One of the side effects with the use of dexmede-
tomidine is severe bradycardia [30–32]. The administration of a
systemic bolus of 1 lg/kg dexmedetomidine initially results in a
transient increase in the blood pressure and reﬂex decrease in
heart rate, especially in younger, healthy patients [33]. It can
be explained, ﬁrstly, by peripheral a2B-adrenoceptor stimula-
tion of vascular smooth muscle and can be attenuated by a
slow infusion over 10 min or more [26]. And secondly, due
to the stimulation of presynaptic a2-adrenoceptors and de-
creased norepinephrine release [34]. In accordance with our re-
sults, these effects were temporary and could be managed
successfully with atropine or ephedrine and volume infusions
[35]. Appropriate patient selection is crucial; patients who
are hypovolaemic, severely vasoconstricted, with ﬁxed stroke
volume, reduced myocardial function, depend on a high level
of sympathetic tone should not receive dexmedetomidine.
Dexmedetomidine seems to have a few respiratory side ef-
fects [36], and receptor binding studies suggest that its effect
on respiration should be minor. Belleville et al. reported epi-
sodes of obstructive apnea in a group of patients who received
high doses of the drug [36]. These effects were seen more com-
monly with doses of 1 or 2 lg/kg given over 2 min, doses that
provide deep sedation. The obstructive respiration pattern and
irregular breathing seen with such doses are probably related
more to deep sedation and anatomical features of the patients,
implying a great caution when using dexmedetomidine in pa-
tients with obstructive sleep apnea syndrome. Moreover, the
coadministration of dexmedetomidine with anesthetic agents,
sedatives, hypnotics, or opioids is likely to cause additive ef-
fects [34]. In our study, no patient exhibited signs of airway
obstruction or prolonged oxygen requirement in PACU. To
avoid conﬂicting results, we excluded from our study patients
with obstructive sleep apnea whether conﬁrmed by polysom-
nography or not. Future studies are needed to investigate the
incidence of airway obstruction in children with obstructive
sleep apnea syndrome receiving dexmedetomidine.
In conclusion, peritonsillar inﬁltration or iv. dexmedetomi-
dine similarly enhanced postoperative analgesia after adeno-
tonsillectomy in pediatric patients. However, the locally
applied dexmedetomidine was associated with no systemic ef-
fects, higher total oral intake in ﬁrst day postoperative, and
higher family satisfaction. For pediatric administration of dex-
medetomidine, appropriate patient and appropriate surgical
procedure selection are crucial. Future studies are needed to
deﬁne the optimum dosage requirements for different pediatric
subpopulations.
Dexmedetomidine analgesia in pediatric tonsillectomy 225Conﬂict of interest
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